The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Why the study?
How should non-vitamin K antagonist oral anticoagulants (NOACs) be optimally used in specific clinical situations for patients with atrial fibrillation?
Population
Patients with atrial fibrillation
Design
Guideline
Authors
Discussion
Loading...
Member takes
Overview
Guides NOAC decisions in 20 AF scenarios now; extends prior EHRA guidance with updated evidence.
Key Points
- Provide updated, practical recommendations to guide clinicians on the safe and effective administration of non-vitamin K antagonist oral anticoagulants in diverse clinical scenarios for patients with atrial fibrillation.
- The European Heart Rhythm Association convened an expert writing committee to evaluate evidence and address unresolved practical questions regarding oral anticoagulant use.
- The committee developed consensus-driven guidance across 20 distinct clinical topics, updating previous practical guides issued in 2013 and 2015.
- Established comprehensive practical workflows for drug initiation, adherence monitoring, switching between regimens, and adjusting therapy for pharmacokinetic drug-drug interactions.
- Formulated protocols for high-risk and specialized scenarios, including chronic kidney disease, advanced liver disease, perioperative management, acute stroke presentations, and active malignancies.
Structured PICO
How should non-vitamin K antagonist oral anticoagulants (NOACs) be optimally used in specific clinical situations for patients with atrial fibrillation?
P
Population
Patients with atrial fibrillation
I
Intervention
Non-vitamin K antagonist oral anticoagulants (NOACs)
This EHRA practical guide provides comprehensive recommendations for the use of NOACs in patients with atrial fibrillation across 20 specific clinical scenarios.
Cite This Study
Steffel et al. (2018) conducted a review in Atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated. The 2018 EHRA Practical Guide provides updated clinical guidance on 20 concrete scenarios for the optimal use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.